In addition, the improvement in NAFLD by GLP-1 correlates with weight loss and other metabolic improvements, and the benefit of GLP-1 agonists for NAFLD may be an indirect effect that acts by improving systemic metabolism, such as improved insulin sensitivity and appetite suppression. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.